Correlation between serum levels of Fibroblast Growth Factor-23 (FGF-23) and parathyroid hormone levels in predialysis Chronic Kidney Disease (CKD) patients at Sanglah General Hospital, Bali, Indonesia

Abstract

Backgrounds: Chronic kidney disease (CKD) is an abnormality in the kidney that lasts for more than 3 months. Increased phosphate levels in the blood due to CKD will stimulate the secretion of Fibroblast Growth Factor 23 (FGF-23). Increased secretion of FGF-23 happens to maintain phosphate balance because the capacity of excretion of phosphorus in the kidneys decreases and leads to the incidence of secondary hyperparathyroidism due to Parathyroid Hormone (PTH). This study aims to evaluate the relationship between serum levels of FGF-23 and PTH in predialysis CKD patients.Methods: An analytical observational study with a cross-sectional approach has been conducted in this study from August until October 2020. Analysis of the relationship between serum levels of Fibroblast Growth Factor (FGF-23) and intact parathyroid hormone using the Spearman correlation test with a significance level of =0.05. Data were analyzed using SPSS version 17 for Windows.Results: A total of 75 people consisting of 49 male participants (65.3%) and 26 female participants (34.7%). The normality test showed that the data were not normally distributed (p<0.05), so the Spearman correlation test was used to evaluate the relationship between FGF-23 and intact PTH. The statistical analysis results showed a low significant positive correlation (r=0.168; p=0.046) between serum levels of FGF-23 and serum levels of intact PTH.Conclusion: There was a low significant positive correlation between FGF-23 and PTH serum levels in predialysis CKD patients.